Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.05
CERS's Cash to Debt is ranked higher than
72% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. CERS: 5.05 )
CERS' s 10-Year Cash to Debt Range
Min: 0.62   Max: 14206.57
Current: 5.05

0.62
14206.57
Equity to Asset 0.58
CERS's Equity to Asset is ranked higher than
69% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CERS: 0.58 )
CERS' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.9
Current: 0.58

0.06
0.9
F-Score: 2
Z-Score: -3.88
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -100.59
CERS's Operating margin (%) is ranked higher than
69% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. CERS: -100.59 )
CERS' s 10-Year Operating margin (%) Range
Min: -2168.13   Max: -7.75
Current: -100.59

-2168.13
-7.75
Net-margin (%) -94.30
CERS's Net-margin (%) is ranked higher than
69% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. CERS: -94.30 )
CERS' s 10-Year Net-margin (%) Range
Min: -1946.68   Max: 53.6
Current: -94.3

-1946.68
53.6
ROE (%) -76.81
CERS's ROE (%) is ranked higher than
60% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. CERS: -76.81 )
CERS' s 10-Year ROE (%) Range
Min: -248.74   Max: 46.03
Current: -76.81

-248.74
46.03
ROA (%) -43.21
CERS's ROA (%) is ranked higher than
64% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. CERS: -43.21 )
CERS' s 10-Year ROA (%) Range
Min: -122.82   Max: 16.26
Current: -43.21

-122.82
16.26
ROC (Joel Greenblatt) (%) -1462.96
CERS's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. CERS: -1462.96 )
CERS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8770.57   Max: -164.15
Current: -1462.96

-8770.57
-164.15
Revenue Growth (%) 1.20
CERS's Revenue Growth (%) is ranked higher than
77% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CERS: 1.20 )
CERS' s 10-Year Revenue Growth (%) Range
Min: -44.7   Max: 52.9
Current: 1.2

-44.7
52.9
EBITDA Growth (%) 17.70
CERS's EBITDA Growth (%) is ranked higher than
90% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CERS: 17.70 )
CERS' s 10-Year EBITDA Growth (%) Range
Min: -52.9   Max: 123.5
Current: 17.7

-52.9
123.5
EPS Growth (%) 15.10
CERS's EPS Growth (%) is ranked higher than
89% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CERS: 15.10 )
CERS' s 10-Year EPS Growth (%) Range
Min: -30.1   Max: 21
Current: 15.1

-30.1
21
» CERS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CERS Guru Trades in Q3 2013

Jim Simons Sold Out
Chuck Royce 4,031,511 sh (-1.47%)
» More
Q4 2013

CERS Guru Trades in Q4 2013

Chuck Royce 3,860,211 sh (-4.25%)
» More
Q1 2014

CERS Guru Trades in Q1 2014

Chuck Royce 3,807,005 sh (-1.38%)
» More
Q2 2014

CERS Guru Trades in Q2 2014

Chuck Royce 3,725,505 sh (-2.14%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.79
CERS's P/B is ranked higher than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CERS: 6.79 )
CERS' s 10-Year P/B Range
Min: 0.82   Max: 55
Current: 6.79

0.82
55
P/S 8.28
CERS's P/S is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. CERS: 8.28 )
CERS' s 10-Year P/S Range
Min: 1.24   Max: 15.91
Current: 8.28

1.24
15.91
EV-to-EBIT -7.32
CERS's EV-to-EBIT is ranked higher than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CERS: -7.32 )
CERS' s 10-Year EV-to-EBIT Range
Min: -77.8   Max: 0.9
Current: -7.32

-77.8
0.9
Current Ratio 3.24
CERS's Current Ratio is ranked higher than
70% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CERS: 3.24 )
CERS' s 10-Year Current Ratio Range
Min: 1.03   Max: 9.96
Current: 3.24

1.03
9.96
Quick Ratio 2.62
CERS's Quick Ratio is ranked higher than
69% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. CERS: 2.62 )
CERS' s 10-Year Quick Ratio Range
Min: 1.03   Max: 9.96
Current: 2.62

1.03
9.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.25
CERS's Price/Net Cash is ranked higher than
81% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. CERS: 17.25 )
CERS' s 10-Year Price/Net Cash Range
Min: 1.88   Max: 103.13
Current: 17.25

1.88
103.13
Price/Net Current Asset Value 11.19
CERS's Price/Net Current Asset Value is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. CERS: 11.19 )
CERS' s 10-Year Price/Net Current Asset Value Range
Min: 1.73   Max: 68
Current: 11.19

1.73
68
Price/Tangible Book 7.26
CERS's Price/Tangible Book is ranked higher than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. CERS: 7.26 )
CERS' s 10-Year Price/Tangible Book Range
Min: 0.92   Max: 300
Current: 7.26

0.92
300
Price/Median PS Value 1.44
CERS's Price/Median PS Value is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CERS: 1.44 )
CERS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 92.9
Current: 1.44

0.24
92.9
Earnings Yield (Greenblatt) -13.70
CERS's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CERS: -13.70 )
CERS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 108.4   Max: 16235.6
Current: -13.7

108.4
16235.6
Forward Rate of Return (Yacktman) -18.08
CERS's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. CERS: -18.08 )
CERS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -174.5   Max: -3.2
Current: -18.08

-174.5
-3.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU2.Germany
Cerus Corporation was incorporated in California in 1991 and reincorporated in Delaware in 1996. It is a biomedical products company which focuses on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. In addition, the Company is developing and plan to perform the required clinical trials for its INTERCEPT Blood System for red blood cells, or red blood cell system, for approval in Europe. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK